AR035682A1 - Piperazinilcarbonilquinolinas e -isoquinolinas, un proceso para su preparacion, las preparaciones farmaceuticas que las contienen, el uso de las mismas para preparar un medicamento, los antagonistas selectivos del receptor de 5-ht2a que conforman estos compuestos y el uso de estos antagonistas en la - Google Patents

Piperazinilcarbonilquinolinas e -isoquinolinas, un proceso para su preparacion, las preparaciones farmaceuticas que las contienen, el uso de las mismas para preparar un medicamento, los antagonistas selectivos del receptor de 5-ht2a que conforman estos compuestos y el uso de estos antagonistas en la

Info

Publication number
AR035682A1
AR035682A1 ARP020100135A ARP020100135A AR035682A1 AR 035682 A1 AR035682 A1 AR 035682A1 AR P020100135 A ARP020100135 A AR P020100135A AR P020100135 A ARP020100135 A AR P020100135A AR 035682 A1 AR035682 A1 AR 035682A1
Authority
AR
Argentina
Prior art keywords
hal
compounds
ht2a
unsubstituted
disease
Prior art date
Application number
ARP020100135A
Other languages
English (en)
Spanish (es)
Inventor
Boettcher Henning Dr
Bartoszyk Gerd Dr
Harting Juergen Dr
Van Amsterdam Christoph Dr
Seyfried Christoph Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR035682A1 publication Critical patent/AR035682A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP020100135A 2001-01-17 2002-01-16 Piperazinilcarbonilquinolinas e -isoquinolinas, un proceso para su preparacion, las preparaciones farmaceuticas que las contienen, el uso de las mismas para preparar un medicamento, los antagonistas selectivos del receptor de 5-ht2a que conforman estos compuestos y el uso de estos antagonistas en la AR035682A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10102053A DE10102053A1 (de) 2001-01-17 2001-01-17 Piperazinylcarbonylchinoline und -isochinoline

Publications (1)

Publication Number Publication Date
AR035682A1 true AR035682A1 (es) 2004-06-23

Family

ID=7670921

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100135A AR035682A1 (es) 2001-01-17 2002-01-16 Piperazinilcarbonilquinolinas e -isoquinolinas, un proceso para su preparacion, las preparaciones farmaceuticas que las contienen, el uso de las mismas para preparar un medicamento, los antagonistas selectivos del receptor de 5-ht2a que conforman estos compuestos y el uso de estos antagonistas en la

Country Status (22)

Country Link
US (1) US7329749B2 (enExample)
EP (1) EP1366039B1 (enExample)
JP (1) JP4417624B2 (enExample)
KR (1) KR100854481B1 (enExample)
CN (1) CN1249055C (enExample)
AR (1) AR035682A1 (enExample)
AT (1) ATE304010T1 (enExample)
BR (1) BR0116774A (enExample)
CA (1) CA2434773C (enExample)
CZ (1) CZ304144B6 (enExample)
DE (2) DE10102053A1 (enExample)
DK (1) DK1366039T3 (enExample)
ES (1) ES2248230T3 (enExample)
HU (1) HU230250B1 (enExample)
MX (1) MXPA03006360A (enExample)
MY (1) MY127293A (enExample)
PL (1) PL212087B1 (enExample)
RU (1) RU2280034C2 (enExample)
SI (1) SI1366039T1 (enExample)
SK (1) SK287333B6 (enExample)
WO (1) WO2002057256A1 (enExample)
ZA (1) ZA200306331B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057435A2 (en) * 2001-01-18 2002-07-25 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
AU2003231032B2 (en) * 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
MXPA04012959A (es) * 2002-06-29 2005-05-16 Zentaris Gmbh Arilcarbonilpiperacinas y heteroarilcarbonilpiperacinas y su uso para tratamiento de enfermedades de tumor benigno y maligno.
US20090311242A1 (en) * 2004-07-29 2009-12-17 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine 2a receptor (5ht2a)
GB2497476B (en) * 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093341A (en) * 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents
US4970714A (en) * 1989-01-05 1990-11-13 International Business Machines Corp. Adaptive data link protocol
EP0957100B1 (en) * 1997-07-07 2004-10-27 Kowa Co., Ltd. Diamine derivatives and pharmaceutical containing the same
CA2342251A1 (en) * 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate

Also Published As

Publication number Publication date
DE60113300D1 (de) 2005-10-13
ES2248230T3 (es) 2006-03-16
CN1486308A (zh) 2004-03-31
KR20030068579A (ko) 2003-08-21
DE60113300T2 (de) 2006-06-29
US20040077657A1 (en) 2004-04-22
HUP0401038A3 (en) 2011-08-29
ATE304010T1 (de) 2005-09-15
KR100854481B1 (ko) 2008-08-26
ZA200306331B (en) 2005-01-26
JP4417624B2 (ja) 2010-02-17
CA2434773A1 (en) 2002-07-25
CZ20031861A3 (cs) 2003-09-17
PL212087B1 (pl) 2012-08-31
WO2002057256A1 (en) 2002-07-25
MY127293A (en) 2006-11-30
EP1366039B1 (en) 2005-09-07
HU230250B1 (hu) 2015-11-30
CA2434773C (en) 2011-10-04
JP2004517145A (ja) 2004-06-10
CZ304144B6 (cs) 2013-11-20
CN1249055C (zh) 2006-04-05
HK1061849A1 (en) 2004-10-08
SK8652003A3 (en) 2003-11-04
WO2002057256A9 (en) 2005-12-08
SK287333B6 (sk) 2010-07-07
US7329749B2 (en) 2008-02-12
PL361741A1 (en) 2004-10-04
RU2280034C2 (ru) 2006-07-20
MXPA03006360A (es) 2003-10-06
SI1366039T1 (sl) 2006-02-28
HUP0401038A2 (hu) 2004-08-30
DK1366039T3 (da) 2006-01-02
BR0116774A (pt) 2004-01-06
DE10102053A1 (de) 2002-07-18
RU2003124077A (ru) 2005-01-10
EP1366039A1 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
AR024819A1 (es) Derivados de la n-(indolcarbonil)-piperazina, un procedimiento para su preparacion, su empleo para preparar un medicamento, los medicamentos a base de los mismos y las preparaciones farmaceuticas que los contienen.
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
KR20140010012A (ko) 글루코세레브로시다제 활성제로서 치환된 피라졸로피리미딘
ES2058292T3 (es) Derivados de indol.
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
BG104960A (en) Bicyclic pirimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
ES2058630T3 (es) Derivados de 2-(1-piperazinil)-4-fenilcicloalcanopiridinas, procedimientos de preparacion y composiciones farmaceuticas que los contienen.
RU2007138264A (ru) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
ES2187983T3 (es) Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
PA8495101A1 (es) Derivados de 13-metileritromicina
HUT48589A (en) Process for production of new derivatives of substituated n-/1-hydroxi-4-piperidinil/-benzamid
UY23624A1 (es) Procedimiento para la preparacion de nuevos derivados de indol
AR026974A1 (es) N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen
AR006360A1 (es) Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion.
ES2067874T3 (es) Derivados de acetamida.
ES2028802T3 (es) Procedimiento para preparar compuestos fenil(o heterociclo) tetrahidropiridil(o piperazinil)alcoxi-benzoheterociclicos utiles como antipsicoticos.
AR021662A1 (es) Derivados de la piperazina, proceso para prepararlos. las composiciones farmaceuticas que los contienen y la utilizacion de las mismas como medicamentoso para la preparacion de medicamentos
AR019674A1 (es) Compuestos antitromboticos y composiciones farmaceuticas que los contienen
BR9812239A (pt) Composto, formulação farmacêutica, uso do composto, processos para o tratamento de distúrbios, para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e, para a preparação do composto
AR027578A1 (es) Derivados de indano
ATE384708T1 (de) Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren
AR054000A1 (es) Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo
MX9405110A (es) Nuevos derivados de (1-heteroazolil-1-heterociclil)alcano y su uso comoagentes neuroprotectores.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee